[Skip to Navigation]
Views 965
Citations 0
JAMA Oncology Clinical Challenge
March 25, 2021

Lower Back Pain in a Patient With Sarcoma

Author Affiliations
  • 1Department of Radiology, University Hospital, LMU Munich, Munich, Germany
  • 2Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
JAMA Oncol. Published online March 25, 2021. doi:10.1001/jamaoncol.2020.8080

A 39-year-old female patient with alveolar rhabdomyosarcoma and bone metastases presented in April 2020 with lower back pain, which was aggravated while standing and walking. She reported no known trauma, and no motor or sensory deficits were noted during clinical examination. She had no fever.

After the initial sarcoma diagnosis in September 2018, the patient received 8 cycles of doxorubicin hydrochloride and ifosfamide along with regional hyperthermia, followed by good tumor response. The patient had a history of a pathological fracture of L4, which had been treated with radiotherapy and vertebroplasty in November 2019 and remained unchanged on imaging obtained in April 2020. The treatment regimen recently had been switched to gemcitabine hydrochloride and docetaxel in January 2020 following osseous progression during maintenance chemotherapy with trofosfamide, idarubicin hydrochloride, and etoposide.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×